[Coagulopathy and COVID-19. Recommendations for a changing reality]
Related Experiment Video
Updated: Dec 6, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
Dardo Riveros1, Daniela Maymó1, Julia Laviano1
1Servicio de Hematología, Medicina Transfusional y Trasplante de Médula ósea, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (CEMIC), Buenos Aires, Argentina.
Insights
Critically ill COVID-19 patients face increased risks of blood clots and organ failure due to a hypercoagulable state. This study reviews evidence to recommend treatments for coagulopathy, aiming to reduce COVID-19 patient mortality.
Area of Science:
- Critical care medicine
- Hematology
- Infectious diseases
Background:
- Coronavirus disease 2019 (COVID-19) is associated with a significant risk of thromboembolic events.
- Critically ill patients with SARS-CoV-2 infection exhibit a hypercoagulable state, evidenced by elevated D-dimer levels.
- This hypercoagulability correlates with increased risks of organ failure and mortality.
Purpose of the Study:
- To analyze the scientific evidence regarding the therapeutic management of coagulopathy in COVID-19.
- To develop evidence-based recommendations for treating COVID-19-associated coagulopathy.
- To reduce patient morbidity and mortality through optimized therapeutic strategies.
Main Methods:
- Systematic review of available scientific literature.
- Analysis of hemostatic abnormalities in SARS-CoV-2 infected patients.
- Evidence synthesis for therapeutic decision-making.
Main Results:
- COVID-19 induces a hypercoagulable state with elevated D-dimer.
- Thromboembolism risk is elevated in critically ill COVID-19 patients.
- Hemostatic abnormalities are critical factors in patient outcomes.
Conclusions:
- Therapeutic decisions for COVID-19 patients must consider hemostasis abnormalities.
- Evidence-based recommendations are crucial for managing coagulopathy.
- Targeted interventions can potentially decrease COVID-19 morbidity and mortality.
Abstract:
The coronavirus disease 2019 (COVID-19) pandemic requires rapid medical responses. The risk of venous and arterial thromboembolism increases in critically ill patients with SARS-CoV-2 infection. There is a hypercoagulable state that includes elevated levels of D-dimer, with an increased risk of organ failure and increased mortality. The abnormalities described in hemostasis should be considered for therapeutic decision making. We analyzed the available scientific evidence for the therapeutic approach of coagulopathy in the course of the disease with the objective of designing realistic therapeutic recommendations aimed at reducing morbidity and mortality in patients with COVID-19.
More Related Videos
Related Concept Videos
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins

